SnapDandCGMinType2DM

Inclusion Criteria: 1. Aged 18 to 65 years, male or female at birth 2. Diagnosed with type 2 Diabetes Mellitus with overweight or obesity (BMI\>23 kg/m²) 3. Hemoglobin A1c (HbA1c) 6.5-9% measured within 3 months prior to the screening date 4. Willing to maintain their current antidiabetic medication regimen without dose adjustment for the entire 8-week study duration 5. Must possess an internet-enabled devices e.g. smartphone, tablet compatible with the SnapD application 6. Able and willing to adhere intervention, including using snapD and CGM Exclusion Criteria: 1. Currently pregnant, plan pregnancy or breastfeeding during the 8-week study period 2. Current participation in another interventional clinical trial 3. Current use of insulin or incretin-based therapies (e.g., GLP-1 Receptor Agonists, GIP/GLP-1 Receptor Agonists) 4. Presence of severe hearing or visual impairment that, in the investigator's judgment, would preclude the participant from safely and effectively using the SnapD application or the CGM device 5. known contraindication to CGM usage e.g., a history of severe hypersensitivity to the device's materials or adhesive, planing to go on CT-contrasted imaging etc.